Skip to main content
Equibles
SCNI logo

SCNI · Scinai Immunotherapeutics Ltd.

Track SCNI — free

Use SCNI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SCNI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.66 -0.02 (-3.10%)
Rebalance outlook locked
Market Cap
$921,954
Shares
1.35M
Volume · Oct 21 12.93K Avg daily vol (42 sessions) 3.24M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.68 Open$0.74 Day$0.67–0.74 52W close$0.68–15.10 Avg vol 30d4.4M Short int20K · 1.5% float · 1.0d Short vol26% DataJan 2020–Oct 2026 Filing10-Q · May 15

Up next

Latest filing: 10-Q
filed May 15, 2023

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.49M
Trailing 12 months
Net income (TTM)
−$2.60M
Trailing 12 months
Revenue growth YoY
+99.2%
Year over year
Operating margin
-564.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-739.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+81.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.5%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −86%
below
Price vs 50-day avg −63%
below
RSI (14) 27
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −64%
trailing
6-month return −90%
trailing
YTD return −90%
this year
Relative strength −99%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+175% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.47% of float · ▼ -95.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
11 holders — mid 3-yr range
Squeeze score 35
low risk · 0–100
Fundamentals
Weak
Revenue growth +99%
Y/Y
Gross margin -202%
contracting
EPS growth −60%
Y/Y
Free cash flow $-6.1M
Quant / Vol
risk profile
Very High
Volatility 136%
annualized · 1-yr
Max drawdown −95%
past year
ATR 32.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−86% Bearish
Price vs 50-day avg
−63% Bearish
RSI (14)
27 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+175% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.47% of float · ▼ -95.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
11 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $15
vs 200-day avg -86% vs 50-day avg -63%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SCNI
Scinai Immunotherapeutics Ltd.
this stock
$921,954 — +99.2% — 1.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $96.65B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.13B +4.6% +20.8% 20.0 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
11
% held
1.4%
Net QoQ
+16.3K sh
Top holder
CITADEL ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Falling
Shares short
19.9K
Days to cover
1.0d
Change
-431.7K sh
View
Short Volume
Short vol %
26%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
100
Value
$141
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
49.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.3M
Net income (FY)
$-8.3M
EPS diluted
$0.04
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 20, 2026
This year
21

Scinai Immunotherapeutics Ltd. reported approximately $5.1 million in committed service fees, Committed Customer Orders of approximately $8.1 million, and approximately $5.3 million in financing proceeds, supporting an operating runway to late 2027 that may extend into the third quarter of 2028.

View
Exempt Offerings
Offering
$1.7M
Filed
Jan 12, 2024
View

Performance

5D 20D 120D MTD YTD
SCNI -44.6% -64.3% -90.5% -52.0% -90.4%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -43.5% -63.8% -98.5% -52.9% -103.2%
Key facts CIK 1611747 CUSIP 09073Q402 Visit website Investor relations